ACKR3 and non-small cell lung carcinoma: We showed that upon treatment with gefitinib, CXCR7 expression dramatically decreased in EGFR-mutant NSCLC cell lines, but, conversely, it is increased in EGFR wild-type NSCLC cell lines.